Jefferies initiated coverage of Tourmaline Bio with a Buy rating and $41 price target. Tourmaline is a clinical stage biotech company developing IL-6 treatment for thyroid eye disease and beyond, the analyst tells investors in a research note. The firm says IL-6 has shown efficacy in retrospective and observational studies in TED, and that the company’s lead asset TOUR006 is a potential best-in-class antibody.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRML:
